These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12930449)

  • 1. Neuroendocrine differentiation in prostate cancer: is it detectable and treatable?
    Birtle AJ; Freeman A; Payne HA; Masters JR; Harland SJ
    BJU Int; 2003 Sep; 92(4):490. PubMed ID: 12930449
    [No Abstract]   [Full Text] [Related]  

  • 2. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
    Isshiki S; Akakura K; Komiya A; Suzuki H; Kamiya N; Ito H
    J Urol; 2002 Feb; 167(2 Pt 1):512-5. PubMed ID: 11792908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum chromogranin A in prostate cancer. Preliminary results].
    Reale MG; Marchei GG; Boccia S; Cristofoletti C; Caporossi E; Marchei M; Izzo P; Marchei P
    Minerva Med; 1999; 90(7-8):221-3. PubMed ID: 10719423
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum chromogranin A in prostate cancer].
    Akakura K
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():160-4. PubMed ID: 12599564
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
    Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A
    Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated plasma chromogranin-A concentrations in prostatic carcinoma.
    Kadmon D; Thompson TC; Lynch GR; Scardino PT
    J Urol; 1991 Aug; 146(2):358-61. PubMed ID: 1856931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogranin A in human disease.
    O'Connor DT; Mahata SK; Taupenot L; Mahata M; Livsey Taylor CV; Kailasam MT; Ziegler MG; Parmer RJ
    Adv Exp Med Biol; 2000; 482():377-88. PubMed ID: 11192598
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
    Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
    J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
    Yashi M; Tokue A
    J Urol; 2003 Jun; 169(6):2305; author reply 2305. PubMed ID: 12771784
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
    Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
    Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
    Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
    J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I; Pinthus Y; Sella BA; Ramon J
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination.
    Fracalanza S; Prayer-Galetti T; Pinto F; Navaglia F; Sacco E; Ciaccia M; Plebani M; Pagano F; Basso D
    Urol Int; 2005; 75(1):57-61. PubMed ID: 16037709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer.
    Deftos LJ
    Prostate Suppl; 1998; 8():23-31. PubMed ID: 9690660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas.
    Tsao KC; Wu JT
    Clin Chim Acta; 2001 Nov; 313(1-2):21-9. PubMed ID: 11694235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
    Chuang CK; Wu TL; Tsao KC; Liao SK
    J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.